Skip to Content

Auranofin

Pronunciation

(au RANE oh fin)

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Ridaura: 3 mg [contains benzyl alcohol]

Brand Names: U.S.

  • Ridaura

Pharmacologic Category

  • Gold Compound

Pharmacology

The exact mechanism of action of gold is unknown; gold salts decrease cellular proliferation, reduce antibody and cytokine release, and inhibit collagenase action (Doan 2005).

Absorption

Oral: ~25% gold in dose is absorbed

Metabolism

Rapid; intact auranofin not detectable in the blood

Excretion

Urine (~60% of absorbed gold); remainder in feces

Onset of Action

Delayed; therapeutic response may not be seen for 3-4 months after start of therapy, as long as 6 months in some patients

Time to Peak

Serum: ~2 hours (Blocka 1986)

Duration of Action

Prolonged

Half-Life Elimination

Single or multiple dosing dependent: 21-31 days

Protein Binding

60%

Use: Labeled Indications

Rheumatoid arthritis: Management of adult patients with active stage classic or definite rheumatoid arthritis in patients who do not respond to or tolerate an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs (NSAIDs)

Contraindications

History of gold-induced disorders, including anaphylactic reactions, bone marrow aplasia, severe hematologic disorders, exfoliative dermatitis, necrotizing enterocolitis, or pulmonary fibrosis.

Dosing: Adult

Rheumatoid arthritis: Oral: Initial: 6 mg/day in 1-2 divided doses; after 6 months may be increased to 9 mg/day in 3 divided doses; discontinue therapy if no response after 3 months at 9 mg/day

Note: Signs of clinical improvement may not be evident until after 3 months of therapy.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment

There are no dosage adjustments provided in the manufacturer’s labeling. The following guidelines have been used by some clinicians (Aronoff 2007):

GFR >50 mL/minute: Administer 50% of dose.

GFR ≤50 mL/minute: Avoid use.

Dosing: Hepatic Impairment

There are no dosage adjustments provided in the manufacturer’s labeling.

Storage

Store at 15°C to 30°C (59°F to 86°F). Protect from light.

Drug Interactions

There are no known significant interactions.

Adverse Reactions

>10%:

Dermatologic: Skin rash (24%), pruritus (17%)

Gastrointestinal: Diarrhea (≤47%), loose stools (≤47%), abdominal pain (14%), stomatitis (13%)

1% to 10%:

Dermatologic: Alopecia (1% to 3%), urticaria (1% to 3%)

Gastrointestinal: Nausea (10%), vomiting (10%), anorexia (3% to 9%), dyspepsia (3% to 9%), flatulence (3% to 9%), constipation (1% to 3%), dysgeusia (1% to 3%), glossitis (1% to 3%)

Genitourinary: Proteinuria (3% to 9%), hematuria (1% to 3%)

Hematologic and Oncologic: Anemia (1% to 3%), eosinophilia (1% to 3%), leukopenia (1% to 3%), thrombocytopenia (1% to 3%)

Hepatic: Increased serum transaminases (1% to 3%)

Ophthalmic: Conjunctivitis (3% to 9%)

<1% (Limited to important or life-threatening): Agranulocytosis, aplastic anemia, angioedema, bronchitis (gold), corneal deposits, dysphagia, exfoliative dermatitis (other gold compounds), fever, gastrointestinal hemorrhage, gingivitis, hepatotoxicity, interstitial pneumonitis, jaundice, metallic taste, melena, neutropenia, pancytopenia, peripheral neuropathy, pure red cell aplasia, ulcerative enterocolitis

ALERT: U.S. Boxed Warning

Gold toxicities:

Auranofin contains gold and, like other gold-containing drugs, can cause gold toxicity, signs of which include: Fall in hemoglobin, leukopenia <4000 WBC/mm3, granulocytes <1500/mm3, decrease in platelets <150,000/mm3, proteinuria, hematuria, pruritus, rash, stomatitis or persistent diarrhea.

Appropriate use:

Like other gold preparations, auranofin is only indicated for use in selected patients with active rheumatoid arthritis.

Experienced physician:

Physicians planning to use auranofin should be experienced with chrysotherapy and should thoroughly familiarize themselves with the toxicity and benefits of auranofin.

Monitoring:

The results of recommended laboratory work should be reviewed before writing each auranofin prescription. In addition, the following precautions should be routinely employed: The possibility of adverse reactions should be explained to patients before starting therapy and patients should be advised to report promptly any symptoms suggesting toxicity.

Warnings/Precautions

Concerns related to adverse effects:

• Dermatologic reactions: [US Boxed Warning]: Signs of gold toxicity include pruritus, rash, and stomatitis. Stomatitis and dermatitis are common reactions and may be serious (including exfoliative dermatitis). Pruritus and metallic taste may occur before dermatitis and oral mucous membrane reactions, respectively, and should be considered warning signs. Stomatitis may be manifested by shallow ulcers on the buccal membranes, on border of tongue, and on palate or in the pharynx; sometimes diffuse glossitis or gingivitis develops. Gold dermatitis may be aggravated by sunlight exposure or an actinic rash may develop. Use with caution in patients with skin rash; may increase risk and/or symptoms of gold toxicity and toxicity may be more difficult to detect.

• Gastrointestinal effects: [US Boxed Warning]: Signs of gold toxicity include persistent diarrhea/loose stools, as well as nausea, vomiting, anorexia, abdominal cramps, and ulcerative enterocolitis (rare). Diarrhea may be managed with a dose reduction. Use with caution in patients with inflammatory bowel disease; may increase risk and/or symptoms of gold toxicity and toxicity may be more difficult to detect. Monitor patients for GI bleeding.

• Hematologic effects: [US Boxed Warning]: Signs of gold toxicity include hematologic depression (decreased hemoglobin, leukocytes (WBC <4000/mm3), granulocytes (<1500/mm3), or decreased platelets (<150,000/mm3). Use with caution in patients with bone marrow depression; may increase risk and/or symptoms of gold toxicity and toxicity may be more difficult to detect. Therapy should be discontinued if signs and symptoms (eg, purpura, ecchymoses, petechiae) of thrombocytopenia develop or if platelet count falls to <100,000/mm3; therapy should not be reinitiated until thrombocytopenia resolves and if thrombocytopenia was not caused by the gold therapy.

• Hepatic effects: May be associated with the development of cholestatic jaundice (rare). Use with caution in patients with hepatic impairment; may increase risk and/or symptoms of gold toxicity and toxicity may be more difficult to detect.

• Pulmonary toxicity: May be associated with rare reactions, including gold bronchitis, interstitial pneumonitis and fibrosis; monitor closely.

• Renal effects: [US Boxed Warning]: Signs of gold toxicity include proteinuria and hematuria. Renal toxicity ranges from mild proteinuria to nephrotic syndrome or glomerulitis with proteinuria and hematuria. Use with caution in patients with renal impairment; may increase risk and/or symptoms of gold toxicity and toxicity may be more difficult to detect. Therapy should be discontinued promptly if proteinuria or microscopic hematuria develops.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.

Other warnings/precautions:

• Appropriate use: [US Boxed Warning]: Use is only indicated in select patients with active rheumatoid arthritis.

• Experienced physician: [US Boxed Warning]: Physicians should be experienced with chrysotherapy and should be familiar with the toxicity and benefits of therapy.

• Monitoring: [US Boxed Warning]: Laboratory monitoring should be reviewed prior to each new prescription. The possibility of adverse reactions should be discussed with patients prior to starting therapy and patients should be advised to promptly report any symptoms suggesting toxicity. Disease states should be stable prior to initiating therapy.

Monitoring Parameters

Patients should have baseline CBC with differential, platelet count, renal function tests, liver function tests, and urinalysis; CBC with differential, platelet count and urinalysis should also be monitored monthly during therapy. Skin and oral mucosa should be inspected for skin rash, bruising or oral ulceration/stomatitis. Specific questioning for symptoms such as pruritus, rash, stomatitis or metallic taste should be included.

Pregnancy Risk Factor

C

Pregnancy Considerations

Adverse events were observed in animal reproduction studies.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience lack of appetite, nausea, vomiting, abdominal cramps, flatulence, or mouth irritation. Have patient report immediately to prescriber signs of kidney problems (urinary retention, hematuria, change in amount of urine passed, or weight gain), severe abdominal pain, skin irritation, severe loss of strength and energy; bruising; bleeding; hematuria; itching; rash; severe diarrhea; signs of infection; black, tarry, or bloody stools; vomiting blood; vision changes; eye pain; or severe eye irritation (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.

Hide